Biotech Values

[bladerunner1717]

From the COR board:

"My information is that the LLY compounds bind to a section of the AMPA receptor which is very near an area that is often epileptogenic--and they were gambling that it wasnt so close that it would trigger it--no such luck. The area they were targeting also appears to be related to a higher degree of neurotrophin release--which is why they were willing to walk the high-impact tightrope. Cortex's low impact Ampakines do not bind to this area--even at very high doses, no seizure activity seen. The question is: is Cortex's knowledge of AMPA receptor structure, and their ability to design highly specific compounds accordingly, better than their competitors in the high impact area? I'm willing to bet on Lynch, Rogers, et al." ---Neuroinv


Bladerunner